PYMNTS.com October 16, 2024

Google DeepMind has developed an AI model to predict key properties of potential drugs, aiming to accelerate pharmaceutical research.

The new Tx-LLM (Therapeutic Large Language Model) model exemplifies a shift toward specialized artificial intelligence tools for specific industries. This targeted approach could prove more valuable than general-purpose AI in addressing complex commercial challenges.

“Industry-specific AI models are fundamentally reshaping business operations by leveraging the nuances of individual industries,” Adnan Masood, chief AI architect at UST, told PYMNTS.

Tx-LLM is an example of AI model fine-tuning, which involves taking a pre-trained model and refining it on a specific task or dataset to improve its performance in that area. This process allows the model to adapt to specialized needs without being built...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
Mobile Threats, AI Innovation, Third-Party Risks: Trends Shaping Healthcare In 2025
The Future Of Work: When Human Expertise Meets AI Capabilities
Samsung’s C-Lab to Showcase AI and Health Projects at CES
Foxconn Invests in AI Data Center Firm Zettabyte to Boost Sustainable Computing
DeepSeek-V3, ultra-large open-source AI, outperforms Llama and Qwen on launch

Share This Article